Tri-drug therapy of arterial hypertension – internal medicine point of view Review article
Article Sidebar
Main Article Content
Abstract
Arterial hypertension is common condition in patients admitted to medical words. Optimal pharmacotherapy in those patients is often difficult to obtain because of many coexisting diseases. Those coexisting conditions as far as potential contraindications have to be taken into consideration. Pharmacotherapy has to be not only efficient but also good tolerated. It is often easy to obtain polipragmazy instead of polipharmacotherapy. In hypertensive patients triple pharmacotherapy is often needed. Fix dose of perindoprile, amlodipine and indapamide sustain release can be optimal choice in many of those patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Wieczorowska-Tobis K., Rajska-Neumann A.: The challenges of geriatric pharmacotherapy. Terapia 2010; 18(10): 24-27.
3. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. Prakt. 2015; 1: 1-70.
4. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782-788.
5. Mancia G., Asmar R., Amodeo C. et al.: Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J. Hypertens. 2015; 33(2): 401-411.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
7. Beckett N.S., Peters R., Fletcher A.E.; HYVET Study Group: Treatment of Hypertension in Patients 80 Years of Age or Older. N. Engl. J. Med. 2008; 358: 1887-1898.
8. Tóth K.; PIANIST Investigators: Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am. J. Cardiovasc. Drugs 2014: 137-145.
9. Bansal S., Chauhan D.K., Ramesh D. et al.: Blood pressure control and acceptability of perindopril and its fixed dose combinations with amlodipine or indapamide, in younger patients with hypertension. Indian Heart J. 2014; 66(6): 635-639.
10. Páll D., Szántó I., Szabó Z.: Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin. Drug. Investig. 2014; 34(10): 701-708.